99% Supply Hair Loss Treatment WAY 316606 White Powder Antiosteoporotic agents

Place of Origin China
Brand Name XRD
Certification GMP
Model Number 915759-45-4
Minimum Order Quantity negotiable
Price Inquiry for Negotiable
Packaging Details 1-2 kg / aluminum foil bag, 25kg/ drum, as required
Delivery Time 1-2days after payment received
Payment Terms T/T bank, Western Union, Bitcoin, Etc
Supply Ability 100KG/ Month

Contact me for free samples and coupons.

Whatsapp:0086 18588475571

Wechat: 0086 18588475571

Skype: sales10@aixton.com

If you have any concern, we provide 24-hour online help.

Product Details
Product Name WAY 316606 CAS 915759-45-4
Type Hair Loss Appearance White Powder
Usage Hair Loss Treatment Alias WAY 316606
Assay 99% Min Key Words WAY 316606
High Light

raw materials for pharma industry


pharmaceutical grade raw materials

Leave a Message
Product Description

99% Supply Hair Loss Treatment WAY 316606 White Powder Antiosteoporotic agents



1. Product description:



Product name:BenzenesulfonaMide, 5-(phenylsulfonyl)-N-4-piperidinyl-2-(trifluoroMethyl)- / WAY316606


Molecular Formula:C18H19F3N2O4S2

Molecular Weight:448.4796696





WAY 316606WAY 316606 is a sFRP-1 (Secreted frizzled-related proteins) inhibitor (Ki=80 nM); an endogenous antagonist of the secreted glycoprotein Wnt. IC50 value: 80 nM (Kd); 0.65 uM (EC50)Target: sFRP-1 Research showed that WAY 316606 bound to sFRP-1 with a K(D) of 0.08 microM and inhibited it with an EC(50) of 0.65 microM. WAY 316606 increased total bone area in a murine calvarial organ culture assay at concentrations as low as 0.0001 microM. Antiosteoporotic agents.



Supply Hair Loss Treatment WAY 316606/ CAS 915759-45-4/way-316606/way 316-606 buy




WAY 316606
Description: Secreted Frizzled-related protein-1 (sFRP-1) inhibitor; increases Wnt signaling

Cortexolone 17 alpha-propionate (CB-03-01) is a new topical and peripherally selective androgen receptor antagonist.

RU 58841
RU58841 works by binding to the androgen receptor in the hair follicle. Therefore androgens don't have the chance to bind and start the chain reaction of androgenetic alopecia and begin the so called miniaturization process. It has been demonstrated to interrupt this hair loss message locally so that normal hair growth could continue.

OC000459 for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of OC000459 have focused on different chemical forms of the drug and combining it with various nanoparticles to enhance delivery. Recent years have seen the odd study pop up in relation to OC000459 and the treatment of acne and prostate cancer, which are conditions also driven by, however, the most recent study published in relation to OC000459 was back in 2008.

Setipiprant is an orally available, selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T helper [Th]-2 cells) antagonist. CRTH2 is a G protein-coupled receptor for prostaglandin (PGD2). PGD2 is produced by the mast cells and is a key mediator in various inflammatory diseases, including allergy and asthma. Binding of PGD2 to CRTH2, which are expressed on the surface of blood-borne cells, induces chemotaxis of Th2 cells, basophils, and eosinophils, and stimulates cytokine release from these cells. Thus, antagonism of CRTH2 receptors is considered to be a promising therapeutic target for various allergic diseases and asthma.

Fevipiprant, also known as NVP-QAW039 or QAW039, is an oral active and potent CRTh2 receptor antagonist and potentially useful for asthma treatment. [(3)H]-QAW039 displayed high affinity for the human CRTh2 receptor (1.14 ± 0.44 nM) expressed in Chinese hamster ovary cells, the binding being reversible and competitive with the native agonist prostaglandin D2(PGD2). QAW039 was also a potent inhibitor of PGD2-induced cytokine release in human Th2 cells. Fevipiprant reduces eosinophilic airway inflammation and is well tolerated in patients with persistent moderate-to-severe asthma and raised sputum eosinophil counts despite inhaled corticosteroid treatment. Fevipiprant demonstrates a favorable safety profile.



99% Supply Hair Loss Treatment WAY 316606 White Powder Antiosteoporotic agents 1




99% Supply Hair Loss Treatment WAY 316606 White Powder Antiosteoporotic agents